Factors Influencing Residual Pleural Opacity in Tuberculous Pleural Effusion

다국어 초록 (Multilingual Abstract)

Tuberculous pleural effusion (TPE) leads to residual pleural opacity (RPO) in a significant
proportion of cases. The aim of this study was to investigate which TPE
patients would have RPO following the treatment. This study was performed prospectively
for a total of 60 TPE patients, who underwent pleural fluid analysis on the initial
visit and chest radiographs and computed tomography (CT) scans before and
after the administration of antituberculous medication. At the end of antituberculous
medication, the incidence of RPO was 68.3% (41/60) on CT with a range of
2-50 mm. Compared with the non-RPO group, the RPO group had a longer symptom
duration and lower pleural fluid glucose level. On initial CT, loculation, extrapleural
fat proliferation, increased attenuation of extrapleural fat, and pleura-adjacent
atelectasis were more frequent, and parietal pleura was thicker in the RPO group
compared with the non-RPO group. By multivariate analysis, extrapleural fat proliferation,
loculated effusion, and symptom duration were found to be predictors of
RPO in TPE. In conclusion, RPO in TPE may be predicted by the clinico-radiologic
parameters related to the chronicity of the effusion, such as symptom duration and
extrapleural fat proliferation and loculated effusion on CT.

참고문헌 (Reference)

1 Barbas CS, "The relationship between pleural fluid findings and the development of pleural thickening in patients with pleural tuberculosis" 100 : 1264-1267, 1991

2 Uskul B, "The relation of the pleural thickening in tuberculosis pleurisy with the activity of adenosine deaminase" 63 : 101-107, 2005

3 Kunter E, "The effect of pleural fluid content on the development of pleural thickness" 6 : 516-522, 2002

4 Moon JW, "The clinical utility of polymerase chain reaction for the diagnosis of pleural tuberculosis" 41 : 660-666, 2005

5 Han DH, "Resolution of residual pleural disease according to time course in tuberculous pleurisy during and after the termination of antituberculosis medication" 128 : 3240-3245, 2005

6 Yew WW, "Prediction of residual pleural thickening in tuberculous pleural effusion" 7 : 199-200, 2003

7 Sahn SA, "Pleural thickening, trapped lung, and chronic empyema as sequelae of tuberculous pleural effusion: don’t sweat the pleural thickening" 6 : 461-464, 2002

8 Lai YF, "Pigtail drainage in the treatment of tuberculous pleural effusions: a randomised study" 58 : 149-151, 2003

9 Waite RJ, "Parietal pleural changes in empyema: appearances at CT" 175 : 145-150, 1990

10 Kim HY, "Parietal pleura and extrapleural space in chronic tuberculous empyema: CT-pathologic correlation" 25 : 9-15, 2001

11 Giusti G, "Methods of enzyme analysis" Academic Press 315-323, 1983

12 Muller NL, "Imaging of the pleura" 186 : 297-309, 1993

13 Candela A, "Functional sequelae of tuberculous pleurisy in patients correctly treated" 123 : 1996-2000, 2003

14 Im JG, "Costal pleura: appearances at high-resolution CT" 171 : 125-131, 1989

15 Lee CH, "Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebocontrolled, randomized study" 94 : 1256-1259, 1988

16 Wyser C, "Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study" 110 : 333-338, 1996

17 de Pablo A, "Are pleural fluid parameters related to the development of residual pleural thickening in tuberculosis?" 112 : 1293-1297, 1997

18 Wang NS, "Anatomy and physiology of the pleural space" 6 : 3-16, 1985